FAP Expression and Its Association with the Prognosis of Gastric Stromal Tumors

TANG Su-min, SHEN Chao-yong, YIN Yuan. et al

Abstract

To determine the association of FAP expression with the prognosis of gastric stromal tumors (GSTs). Methods Paraffin-embedded GSTs samples were collected from January 2010 to December 2013 in the department of pathology of our hospital. FAP expression was examined by immunohistochemistry staining. Its correlations with clinical pathological characteristics and prognosis of GSTs were analyzed. Results A total of 98 cases were included in this study. FAP was expressed in the cytoplasm of GSTs cells, with a positive rate of 42.9%. No FAP expression was found in normal gastric tissues. No differences of FAP expression were found in patients with different gender, age and tumor mitotic counts (P >0.05). Tumor diameter and risk classification were associated with FAP expression (P <0.05). Higher levels of FAP expression were found in larger and higher risk tumors. No significant correlations between FAP expression and routine immunohistochemical markers were found. Log-rank univariate survival analysis showed that mitotic counts, tumor size, postoperative IM and FAP expression were associated with recurrence free survival of GSTs patients with intermediate-high risks (P <0.05). Cox multivariate survival analysis showed that mitotic counts, tumor size, postoperative IM and FAP were independent predictors for the prognosis of GSTs patients with intermediate-high risks (P <0.05). Conclusion FAP is expressed in the cytoplasm of gastric GIST cells, but not in normal gastric tissues. FAP is a predictor for the prognosis of GSTs patients with intermediate-high risks.

 

Keywords: Gastric stromal tumors, FAP, Prognosis 

 

Full Text:

PDF


References


BAIRD SK, ALLAN L, RENNER C, et al. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin- mediated signaling pathways. Clin Exp Metastasis, 2015, 32 (5);507-516.

HAMSONEJ, KEANE FM, THOLEN S, et al. Understanding fibroblast activation protein ( FAP ): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl,2014 .8(5/6) :454-463.

JOENSUU H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008, 39 ( 10): 1411-1419.

YUAN D, LIU B, LIU K. et al. Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma. J Surg Oncol,2013,108(3); 157-162.

NISH IDA T, BLAY JY, HIROTA S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer,2015,19(1): 1-12.

KRAMAN M, BAMBROUGH PJ, ARNOLD JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-a. Science, 2010, 330 (6005):827-830.

WANG H. WU Q, LIU Z, et al. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/ PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis,2014, 5(4):ell55[2016-06-15]. http://www. nature. com/cddis/journal/v5/n4/full/ cddis2014122a. html. doi;10. 1038/cddis. 2014. 122.

A RIG A N, SATO E, OHUCHI N, et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer,2001,95( 1);67-72.

RAMIREZ-MONT AGUT T, BLACHERE NE, SVIDERSKAYA EV, et al. FAPa, a surface peptidase expressed during wound healing, is a tumor suppressor.Oncogene,2004,23(32):5435-5446.

WIKBERG ML. EDIN S, LUNDBERG IV, et at. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol,2013,34(2): 1013-1020.

KIM MC, YOOK JH, YANG HK, et al. Long-term surgical outcome of 1057 gastric gISTs according to 7th UICC/AJCC TNM system: multicenter observational study from Korea and Japan. Medicine (Baltimore) ,2015* 94(41) ; 2085-2094.

MISRA UK, TAN CT, KALITA J. Viral encephalitis and epilepsy. Epilepsia,2008,49(Suppl 6); 13-18.

MICHAEL BD, SOLOMON T. Seizures and encephalitis; Clinical features, management, and potential pathophysiologic mechanisms. Epilepsia,2012,53(Suppl 4): 63-71.

ANNEGERS JF. HAUSER WA, BEGHI E, et al. The risk of unprovoked seizures following encephalitis and meningitis. Neurology, 1988,38(9); 1407-1 110.

YOSHIOKA M, KUROKI S, MIZUE H. Clinical and electroencephalographic studies of postencephalitic epilepsy. Acta Paediatr Jpn, 1989,31(4) :480-483.

LEEWT, YU TW, С HANG WC, et al. Risk factors for postencephalitic epilepsy in children: a hospital-based study in Taiwan. Eur J Paediatr Neurol,2007,11(5) ;302-309.

LIN KL, LIN JJ, HSIA SH, et al. Effect of antiepileptic drugs for acute and chronic seizures in children with encephalitis. PLoS One, 2015, 10 ( 10) : e0139974 [2016-04- 12]. http; //dx. doi. org/10. 1371/journal, pone. 0139974.

STEINER I. BUDKA H. CHAUDHURIA. et al. Viral meningoencephalitis; a review of diagnostic methods and guidelines for management. Eur J Neurol. 2010, 17(8): 999- 1009.

KNEEN R, MICHAEL BD, MENSON E. et al. Management of suspected viral encephalitis in children

Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines. J Infect,2012,64(64) ;449-477.

BERG AT, BERKOVIC SF. BRODIE MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies; report of the I LAE commission on classification and terminology,2005-2009. Epilepsia,2010,51(4) ;676-685.2013,3(5): 17-21 [2015- 12-03]. http://zhkjbykfzz. paperonce. org/oa/DArticle. aspx? type= view8-id = 20130505.

CHEN YJ. FANGPC, CHOW JC. Clinical characteristics and prognostic factors of postencephalitic epilepsy in children. J Child Neurol,2006,21( 12); 1047-1051.


Refbacks

  • There are currently no refbacks.